Summarized by Masters of Longevity from Fight Aging!.
In a 12-week phase 2a trial, rentosertib reduced multiple proteomic age estimates in IPF patients.
Key Takeaways
- A 12-week phase 2a trial found rentosertib lowered proteomic age.
- Pathway analysis showed changes related to senescence and metabolism.
- Proteomic clocks were consistent but cannot isolate disease effects.
